HS-20093

· Hansoh BioMedical R&D Company

Drug timelines are a Plus or Pro feature.

15 regulatory and trial events tracked for HS-20093, covering 2024-07-18 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure [Phase 3]

See pricing